現(xiàn)任首都醫(yī)科大學(xué)附屬北京朝陽醫(yī)院內(nèi)分泌科主任、國家代謝性疾病臨床醫(yī)學(xué)研究中心分中心主任。擔(dān)任中華醫(yī)學(xué)會(huì)內(nèi)分泌學(xué)分會(huì)委員、中國內(nèi)分泌代謝病聯(lián)盟委員、中國醫(yī)師協(xié)會(huì)內(nèi)分泌代謝醫(yī)師分會(huì)委員，北京醫(yī)學(xué)會(huì)內(nèi)分泌學(xué)分會(huì)副主任委員，北京內(nèi)分泌代謝病學(xué)會(huì)糖尿病分會(huì)主任委員。主持國家自然科學(xué)基金5項(xiàng)，北京市自然科學(xué)基金重點(diǎn)項(xiàng)目、首都臨床特色基金等、首都醫(yī)學(xué)發(fā)展基金等。

2022年入選北京市登峰人才;2016年入選第七屆“全國優(yōu)秀科技工作者”;2016年入選北京市“高創(chuàng)計(jì)劃”領(lǐng)軍人才;2015年入選北京市百千萬人才工程市級(jí)人選。以第一完成人獲北京醫(yī)學(xué)科技獎(jiǎng)。

致力于糖尿病、肥胖、甲狀腺疾病的臨床與研究工作。對(duì)糖尿病心血管病變，妊娠甲狀腺疾病、肥胖、腎上腺疾病等有深入系統(tǒng)研究。課題組對(duì)糖尿病促進(jìn)心血管疾病的機(jī)制研究、以及治療手段，處于國際先進(jìn)水平。對(duì)甲狀腺功能減退誘導(dǎo)心肌損傷，甲狀腺激素敏感性降低影響血脂紊亂及同型半胱氨酸代謝，加重心血管損害的研究成果，得到國內(nèi)外認(rèn)可。作為負(fù)責(zé)人，牽頭多項(xiàng)國際、國內(nèi)多中心肥胖臨床研究，對(duì)肥胖狀態(tài)下內(nèi)分泌激素的改變及調(diào)控，有深入的理解，在國際上較早報(bào)道肥胖患者脂肪組織胰島素抵抗與雄激素水平的研究。成果發(fā)表在國際權(quán)威學(xué)術(shù)雜志Nature Medicine (IF：82.9)、Science (IF：56.9)、Metabolism、Eur J Intern Med、J Clin Endocrinol Metab等。第一作者或通訊作者發(fā)表SCI論文100余篇，累計(jì)影響因子600，被SCI引用2000余次。

1. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919-1929. (IF:82.9, Q1)

2. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science, 2023; 381(6657):eadd5787. (IF:56.9, Q1)

3. Correlation between arterial stiffness and coronary flow velocity reserve in subjects with pulse wave velocity >1400 cm/s. Clin Exp Hypertens. 2016;38(1):89-94. (IF: 12.3, Q1)

4. Hydrogen sulfide regulates insulin secretion and insulin resistance in diabetes mellitus, a new promising target for diabetes mellitus treatment? A review. J Adv Res. 2021;27:19-30. (IF:10.7, Q1)

5. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy. Metabolism. 2015;64(3):380-390. (IF: 9.8, Q1)

6. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism. 2007;56(10):1396-1401. (IF: 9.8, Q1)

7. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism. 2005;54(5):590-597. (IF: 9.8, Q1)

8. Chemokine RANTES is upregulated in monocytes from patients with hyperhomocysteinemia. Acta Pharmacol Sin. 2005;26(11):1317-1321. (IF: 8.2, Q1)

9. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease. Diabetes Metab Res Rev. 2015;31(4):329-335. (IF: 8.0, Q1)

10. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism. Eur J Intern Med. 2016;31:94-98. (IF: 8.0, Q1)

11. Sex differences in the association between adipose insulin resistance and non-alcoholic fatty liver disease in Chinese adults, Biol Sex Differ, 2023; 14(1):69. (IF: 7.9, Q1)

12. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab. 2016;42(5):358-363. (IF: 7.2, Q1)

13. Effect of homocysteine on plaque formation and oxidative stress in patients with acute coronary syndromes. Chin Med J (Engl). 2004;117(11):1650-1654. (IF: 6.1, Q1)

14. Vitamin D Deficiency Is Associated with Impaired Sensitivity to Thyroid Hormones in Euthyroid Adults, Nutrients, 2023, 15(17):3697 (IF:5.9, Q1)

15. Reduced sensitivity to thyroid hormones is associated with high remnant cholesterol levels in Chinese euthyroid adults, J Clin Endocrinol Metab. 2022. 108(1):166-174 (IF:5.8, Q1)

16. Impaired sensitivity to thyroid hormones is associated with elevated homocysteine levels in the euthyroid population. J Clin Endocrinol Metab. 2022. 107(9):e3731-e3737 (IF: 5.8, Q1)

17. Sex Differences in the Effect of Testosterone on Adipose Tissue Insulin Resistance from Overweight to Obese Adults. J Clin Endocrinol Metab. 2021. 106(8): 2252-2263 (IF: 5.8, Q1)

18. Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Technol Ther. 2016;18(3):120-126. (IF: 5.4, Q1)

19. Folic acid reverses hyper-responsiveness of LPS-induced chemokine secretion from monocytes in patients with hyperhomocysteinemia. Atherosclerosis. 2005;179(2):395-402. (IF: 5.3, Q2)

20. Serum IL-27 levels increase in subjects with hypothyroidism and are negatively correlated with the occurrence of nonalcoholic fatty liver disease, Front Endocrinol (Lausanne). 2023; 14:1173826. (IF:5.2, Q1)